ClinicalTrials.gg
CompletedNCT00749502Updated Jul 25, 2013

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

A Phase 1 interventional study of MK-4827 in Solid Tumors, Chronic Lymphocytic Leukemia and T-cell-prolymphocytic Leukemia, sponsored by Tesaro, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-25.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a four-part dose-escalation and confirmation study in participants with advanced solid tumors. Part A is for dose escalation and determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of MK-4827. Part B is a prostate/ovarian cancer cohort expansion. Part C is for a cohort of participants with relapsed or refractory T-cell prolymphocytic leukemia (T-PLL) or chronic lymphocytic leukemia (CLL). Part D will be for a cohort of participants with locally advanced or metastatic colorectal carcinoma (CRC), persistent or recurrent endometrial carcinoma, locally advanced or metastatic triple negative or highly proliferative estrogen receptor positive (ER+) breast cancer, or partially platinum-sensitive epithelial ovarian cancer. The study is also designed to find out whether MK-4827 causes at least 50% inhibition of poly adenosine diphosphate ribose polymerase (PARP) enzyme activity.

02

Conditions studied

  • Solid Tumors
  • Chronic Lymphocytic Leukemia
  • T-cell-prolymphocytic Leukemia

Keywords

  • Neoplasms
  • Ovarian neoplasms
  • Prostatic neoplasms
  • Endocrine gland neoplasms
  • Ovarian diseases
  • Adnexal diseases
  • Genital diseases, female
  • Genital diseases, male
  • Genital neoplasms, female
  • Urogenital neoplasms
  • Endocrine system diseases
  • Gonadal disorders
  • Genital neoplasms, male
  • Prostatic diseases
03

In context

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 113 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

First submitted before Tesaro, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part A, participants must have a - or histologically-confirmed or locally advanced solid tumor for which standard therapy does not exist or the participants have refused standard therapy.
  • For Part B, participants must have a cytologically- or histologically-confirmed locally advanced or metastatic prostate cancer for which standard therapy does not exist or the participants have refused standard therapy or sporadic (not known to have BRCA1 or BRCA2 gene mutations) recurrent platinum resistant high grade serous ovarian, primary peritoneal, or fallopian tube cancer. Participants who progressed while receiving a platinum-containing regimen are not eligible. Participants with ovarian cancer must have at least one (at least 15 mm in one dimension) or a cancer antigen (CA)-125 value twice the institutional (ULN).
  • For Part B, participants must have available.
  • For Part C, participants must have a cytologically- or histologically-confirmed diagnosis of T-PLL or B-cell CLL. Participants with T- PLL must have progressed after receiving alemtuzumab. Participants with CLL must have been to or progressed within 12 months following a fludarabine-containing regimen or have received at least 2 prior therapies (before or after the fludarabine containing regimen).
  • For Part D, participants must have:
  • a cytologically- or histologically-confirmed metastatic or locally advanced adenocarcinoma of the colon or rectum (mCRC) and evidence of phosphate and tensin homolog (PTEN) deficiency. Participants must have received at least 1 prior 5-fluoruracil (5-FU)-based combination chemotherapy regimen for mCRC, containing oxaliplatin or irinotecan. Participants must have measurable disease.
  • a cytologically- or histologically-confirmed persistent or recurrent endometrial carcinoma and measurable disease. Participants may not have had more than 1 prior chemotherapy regimen.
  • a cytologically- or histologically-confirmed metastatic or locally advanced sporadic (not known to have a germline BRCA1 or BRCA2 mutation) partially platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Participants who cannot receive platinum due to allergy or toxicity are eligible. Participants with ovarian cancer may have received non-platinum containing chemotherapy between their last platinum-containing regimen and enrolling in this study. Participants must have measurable disease or an elevated CA-125 (at least 2 times the institutional upper limit of normal).
  • a cytologically- or histologically-confirmed metastatic or locally advanced carcinoma of the breast that either lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and (triple negative [TN]) or is ER and/or PR+ . Participants with locally advanced disease must have recurrent or progressive disease that is not suitable for treatment with curative intent. Participants with ER positive disease must have been treated with at least one line of hormonal therapy for recurrent/progressive disease or have been on hormonal therapy at the time of recurrence/progression. Participants with either ER+ or TN tumors may not have had more than 1 for treatment of recurrent disease. If participants received chemotherapy they must have had a disease-free interval of at least 6 months from the completion of adjuvant chemotherapy. Participants must have measurable disease.
  • Participant must have performance status ≤2 on the Performance Scale.
  • Participant must have adequate organ function.
  • Female participants of must have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication.
  • Participants with prostate cancer must continue on luteinizing-hormone-releasing hormone (LHRH) analogues if they have not had an orchiectomy to achieve a sustained baseline serum testosterone \< 50 ng/dL.

Exclusion criteria

Exclusion criteria:

  • Participant who has had chemotherapy, radiotherapy, hormonal or biological therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug.
  • Participant is currently participating or has participated in a study within 30 days or 5 half lives (which ever is longer) of administration of an agent or within 30 days of participating in a study using an investigational device.
  • Participants who have received bevacizumab may enter the trial 4 weeks after their last dose of bevacizumab if all bevacizumab-related toxicities have resolved.
  • Participant with a history of a prior with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with prostatic-specific antigen (PSA) \<1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk for recurrence by his/her treating physician.
  • Participants with known central nervous system (CNS) and/or carcinomatous meningitis are excluded.
  • Participant with a known primary central nervous system tumor.
  • Participant has known to the components of study drug or its analogs.
  • Participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Participant is, at the time of signing , a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
  • Participant is pregnant or breast feeding, or expecting to conceive or father children within the projected duration of the study.
  • Participant is known to be (HIV)-positive.
  • Participant has known history of or C.
  • Participant has symptomatic ascites or a symptomatic pleural effusion.
  • Participant has participated in a clinical trial with a known or putative PARP inhibitor.
  • Participants with T-PLL or CLL with active hemolytic anemia.
  • Participants may not have had therapy with at greater than or equal to 20 mg/day prednisone equivalent within 2 weeks prior to the first dose of treatment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Part A-Dose escalation and confirmation

    Drug: MK-4827

  • Experimental
    Part B - Prostate/Ovarian Cancer Cohort

    Drug: MK-4827

  • Experimental
    Part C - T-PLL/CLL cohort

    Drug: MK-4827

  • Experimental
    Part D - CRC, endometrial, breast, and ovarian cancer cohort

    Drug: MK-4827

Interventions

  • MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs)

    Time frame: Cycle 1 (21 days)

  2. Percent inhibition of peripheral blood mononuclear cell PARP enzyme activity (Part A, B, and C)

    Time frame: Cycle 1 (Days 1-21)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28. PubMed 23810788 ↗
  • Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available. PubMed 23524863 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Sep 2011 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2008
First posted
Sep 9, 2008
Start
Sep 2008
Primary completionActual
Sep 2011
CompletionActual
Jun 2013
Last update
Jul 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00749502
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
Sep 9, 2008
Start date
Sep 2008
Primary completion
Sep 2011
Completion
Jun 2013
Last update
Jul 25, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion